News : drug delivery

View:
 

Found press releases

 

Orexo sells Abstral® in the United States to Galena Biopharma, Inc.

3/18/2013 3:00 AM EST  -   Orexo
Telephone conference March 18 at 1:00pm CET
Uppsala, Sweden – March 18, 2013 – Orexo AB today announced that it sold Abstral® (fentanyl) Sublingual Tablets in the United States to Galena Biopharma, Inc. (NASDAQ: GALE). Under the terms of the agreement, Galena Biopharma will pay Orexo US$10 million upfront and an additional US$5 million within the first twelve months after signing, plus low double digit...
Kytai Nguyen
 

Bioengineer studying how to send drugs to lungs through nanotechnology

1/23/2013 12:33 PM EST  -   University of Texas at Arlington
A UT Arlington bioengineering researcher has teamed with a UT Southwestern colleague to develop a nanoparticle drug delivery system that will help stimulate lung growth and function after partial lung removal or destructive lung disease.

Kytai Nguyen, an associate professor of bioengineering, is working on the drug-delivery portion of the project, which is funded through a $3.4...

Orexo announces positive results supporting OX219 for treatment of opioid depend...

9/21/2011 2:00 AM EST  -   Orexo
Uppsala, Sweden, September 21, 2011 – Orexo AB (STO: ORX) today announced that it has obtained positive results in a clinical study with OX219, which is being developed for the treatment of opioid dependence. The study was designed to decide the commercial formulation and dose for OX219.

Orexo has consulted with the FDA to define the optimal development path for OX219, and will plan to pursue a final drug...

Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific

1/14/2011 2:00 AM EST  -   Orexo
Alliance to Include Commercialization in 11 countries, including Australia and India
Uppsala, Sweden and Singapore – January 14, 2010 – Orexo AB (STO: ORX) and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo’s product for the treatment of breakthrough cancer pain. Under the terms of the agreement,...

Orexo reports phase I trial results for OX219, a novel sublingual tablet formula...

12/14/2010 3:00 AM EST  -   Orexo
Uppsala, Sweden, December 14, 2010 - Orexo AB (STO: ORX) announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence. Global value of the...

Orexo announces new sales figures for Abstral™ from its partner ProStrakan and u...

11/16/2010 2:00 AM EST  -   Orexo
Uppsala, Sweden, November 16, 2010 - Orexo AB (STO: ORX) announces that its sales partner in the EU and USA for Abstral™, ProStrakan Group plc (“ProStrakan”) yesterday issued its interim report, which gave further information on progress with Abstral™, Orexo’s leading sublingual fentanyl product for treatment of breakthrough cancer pain. Abstral™ recorded sales of £14.1m (156 MSEK) in the first 10 months of the...

Orexo appoints Robin Wright as new EVP Head of Finance and Strategy

8/10/2010 5:00 AM EST  -   Orexo
Uppsala, Sweden, August 10, 2010 – Orexo AB (STO: ORX) appoints Robin Wright as EVP Head of Finance replacing Claes Wenthzel who, after five years in the Group, has decided  to leave the company for other assignments. Robin Wright will maintain his current responsibilities of Business Development and he will commence his new role August 20, 2010.

Torbjörn Bjerke, President and CEO, comments: “Robin Wright has,...

Team Consulting speeds medical device certification

7/16/2010 12:50 PM EST  -   Tallis Public Relations
New software development approach reduces costs, risk and time to market

July 16, 2010 Cambridge UK: Leading medical technology firm, Team Consulting, is now offering medical device firms new development options that cut both the cost and risk of medical device certification and decrease the time-to-market.
Team has begun working with SafeRTOS, an embedded operating system from Wittenstein High Integrity...

Orexo reports continued strong AbstralTM sales in Europe

5/18/2010 2:15 AM EST  -   Orexo
Uppsala, May 18, 2010 – Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that AbstralTM continues to show strong sales development in 2010.

AbstralTM was launched across Europe during the course of 2009 and ProStrakan reported sales of £5.8 million in its first year on the market. In the first four months of 2010 AbstralTM has already recorded sales of £5.0 million....

Ponsus Pharma Signs a Nordic Distribution Agreement with Celsus EHF

5/11/2010 10:57 AM EST  -   Ponsus Pharma
Ponsus Pharma signs a product distribution agreement with Celsus EHF for Proderm Sunscreen in Sweden, Iceland and Norway.
STOCKHOLM, May. 11. Ponsus Pharma has signed a product distribution agreement with Celsus EHF to distribute Proderm® Sunscreen in Sweden, Iceland and Norway. Proderm Sunscreen is today available in a SPF6, SPF20 and a SPF30 version. This distribution agreement will make Proderm Sunscreen...